๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Cantargia AB (publ) (STO:CANTA)
Sweden flag Sweden ยท Delayed Price ยท Currency is SEK
1.289
+0.009 (0.70%)
Nov 20, 2026, 5:29 PM CET
โ† View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 10, 2026

Summary

Nadunolimab is advancing in MDS/AML and pancreatic cancer, with ASH data due Dec. 13 and Phase IIa topline results expected by mid-2027. A daraxonrasib combination study targets its first patient in Q1 2027; cash runway extends into mid-2028.

Operator

All right, we're going to get started with the next session here. I'm pleased to introduce CEO of Cantargia, Hilde Steineger. We're going to go through a presentation that's prepared here, and then if time permits, we'll do a little bit of Q&A at the end. Anyone, feel free to ask questions if you wish as well.

Hilde Steineger
CEO, Cantargia

Thank you. Well, good morning, everyone. Hilde Steineger, CEO of Cantargia. We are a listed company, so this is our forward-looking statement. Cantargia is the prominent IL1RAP expert. We were the first company to develop drugs against IL1RAP and so far, we have developed two clinical candidates based on this target. We have more than 500 clones in our library targeting IL1RAP, and importantly, we have been able to monetize on this target by doing a deal with Otsuka a year and a half ago, generating $613 million in bio dollar deals. Inflammatory signaling drives serious disease, yet remains poorly drugged. The challenge has never been to find something to target. It's however, how you target that is meaningful. We think that if you block too narrow, the disease will find a way around the disease.

If you block too broadly, the patient, you risk of dragging the patient's own defense with you. IL1RAP constitutes for us the right way of blocking. IL1RAP is interleukin-1 receptor accessory protein, and it's a co-receptor that binds together with IL-1, IL-33, and IL-36. That means by one single intervention, you can block or target three different inflammatory pathways. This has opened up development path for Cantargia, so we are in the development of both oncology programs and inflammatory programs. Our pipeline is diverse, and our lead asset, nadunolimab, targets both pancreatic cancer, and we have a program together with MD Anderson in leukemic diseases, MDS and AML. I'll walk you through those in a minute. In addition, we have an autoimmune program where our lead candidate, CAN10 was developed for an autoimmune disease and acquired, as mentioned by Otsuka.

The further development of CAN10 is now in the very capable hands of Otsuka. We have also a bispecific that we yesterday announced the second target to, which is IL-17. I'll come back to that later in the presentation. We have a very experienced and broad management team, and the management team has experience from both big pharma, big biotech, and extensive experience from drug development. We recently hired Monic Stuart, who is a licensed hematologist, but also a long tenure in clinical development from companies such as Geron, Genentech, and Revolution Medicines. Turning to myeloid malignancies, more specifically MDS and AML. There are some leukemic stem cells that will survive chemotherapy, and these cells that survive will seed relapse. IL-1 is also driving the proliferation of these leukemic stem cells.

Now, what we think is super important and interesting with our target is that IL1RAP is present at a very high level on the leukemic stem cells, while not on the normal hematopoietic cells. Nadunolimab, by binding to IL1RAP and the interleukin-1 receptor, will inhibit the proliferation of leukemic stem cells. In addition, it labels the cells for immune killing. Not only do we block the proliferation of the leukemic stem cell, we also are able to target for immune killing the sick stem cells and not the normal hematopoietic stem cells. That makes IL1RAP a perfect target to target the malignant cells, but while leaving a reservoir of normal cells. Myelodysplastic syndrome, or MDS is around 400,000 patients worldwide, and it is defined by a blast number in the bone marrow below 20%.

In this 400,000 patient population, the patients that has the high IL1RAP expression is also the patient that are the sickest. That constitute the high and the very high portion of the MDS population. 30%-40% of the high and very high-risk patients will progress into AML. AML is also a disease where there is a high proportion or high expression of IL1RAP in the same cells. The leukemic stem cells. Around 200,000 patients worldwide has AML, and they have a dismal progression. After five years, 10%-30% will have survived. Chemotherapy and stem cells transplantation remains as the standard of care, and there are very few targeted approach, and which we think that biomarkers such as IL1RAP will have an excellent position in the treatment. As mentioned, we are running a phase I-B/II-A in collaboration with MD Anderson, sponsored by the Department of Defense.

MD Anderson submitted an abstract based on June 30th data cut, where 19 patients were evaluated. There were 10 MDS patients and nine AML patients. In the 10 patients of MDS, we saw a 70% response rate. In the three that showed no response, we had two patients that had stable disease because they have been treated only with one cycle of nadunolimab, so it remains to be seen how these two patients progress. In the AML group, we have had 33% response rate, of which one was a complete response, which is highly encouraging in this patient population. The I-B part is now finished, and in that I-B part, of the 19 patients evaluated, only one grade three or four were observed, and that was likely related to nadunolimab, and that was an infusion reaction.

What we are targeting now is that the whole phase II-A will target to include 40 patients, and there will be an interim presentation of this dataset at ASH. This abstract, as shown on this poster here, was chosen as an oral presentation, which is a huge acknowledgement of the importance of the data and the robustness of the data. Turning to PDAC. Pancreatic cancer is still a deadly disease, and there exists very limited treatment options. However, with the approval of daraxonrasib or RASONQUE in August 2026, the field has now a new starting point. Second line has changed as a response to daraxonrasib's data that showed that they could have a nearly doubling of the median overall survival from 6.7 months in chemotherapy group or control arm versus 13.2 in the daraxonrasib arm. However, first line has not still changed.

We expect this to, in the foreseeable future, to include a RAS inhibitor. But for now, the first line is chemotherapy-based. This changing landscape of treatment options puts nadunolimab in an excellent position because we have data, and I'll come back to that next slide, on GN or chemotherapy, and we're embarking on now a combination study with daraxonrasib in the phase I-B setting. In our study, in our 2a study, where we evaluated 73 patients in combination with GN, we saw a 13.2 months overall survival, as compared to GN alone, around 8.5 - 9.2. We saw a 58% that was alive after 12 months. Now, what is interesting in this field is biomarker will play an increasing important role in combination as well with daraxonrasib. We and others have published the importance of selecting patients on high IL1RAP.

If a patient has high IL1RAP, it's a marker for poor prognostics as is illustrated both in Know Your Tumor and also TCGA database. When treated with nadunolimab, we saw an inversion of that trend. So the patient that had high IL1RAP now has a better prognostic value. We then saw a survival rate going from 13.2 - 14.2 in the high IL1RAP group versus the 10.9 in the low IL-1 group. So, not only because the landscape is changing and RAS inhibitor will be an important part of any treatment going forward for PDAC patients, it also makes scientifically perfect sense to combine the two products. KRAS will target the RAS pathway and nadunolimab the inflammatory pathway. Although there are crosstalk among the two different pathways, there are no overlaps.

That means by hitting both pathways, we think we will have an additive and perhaps synergistic effect. We have multiple preclinical data coming out and that we have already produced and also coming out. This slide here illustrates a study performed by Sita Kugel at Fred Hutch in Seattle, where in KPC mice, we could show an additive or an also synergistic effect in the combination. We saw a repolarizing of the cancer-associated fibroblast, a reduction of myeloid cells as shown in the top figure and also we saw an increase in effector cells. All of this ended up reducing the tumor mass in a strong synergistic effect. This figure illustrates nadunolimab alone and RAS inhibitor alone, and only in the combination we could cure mice completely.

What we also saw was a strong reduction in metastasis, and in the combination, again, there was no metastasis observed and only in the combination group. So for us, it makes perfect sense to do a combination study with daraxonrasib, and that is what we are embarking on right now. So daraxonrasib alone will hit the tumor cells and has done a fantastic job with that. However, the shield stays in place. The tumor microenvironment is still there. In addition, resistance will follow. 41% of patients in the RASolute 302 study progressed on daraxonrasib after six months, and a majority of the patients after 12 months. The combination of daraxonrasib plus nadunolimab we think will be able to create this double hit in the pathway, but also reduce the shielding tumor microenvironment, enabling both products to work even better.

Interestingly enough, only in the combination we saw T cells, NK cells, and B cells moving in, and that is an indication that the immune system is starting to fighting back the tumor. The phase I-B will be performed by including metastatic PDAC patients and previously progressed on first-line standard of care, and approximately 15 patients will be included. Primary objective is, of course, to look at safety and tolerability, but we'll also look at preliminary signs of efficacy. We aim to treat the first patient in Q1 next year. A little bit about our discovery engine. As mentioned, we have 500 clones in our library, and two clinical candidates has already been produced. We were the first to develop these drugs for treatment. We're now in the midst of developing a bispecific, where we announced yesterday that our second target is IL-17.

We also have progressed quite nicely with an antibody-drug conjugate that we'll come back to later on, but that will be targeted in oncology. So why IL-17? IL-17 is clinically validated and well-known. However, the combination with IL1RAP has not been tested before, and we think it makes perfect sense to combine the two. IL-17 will drive neutrophilic inflammation, and also the interplay between IL-1 and IL-17 will, we think, be substantiated in chronic inflammatory diseases. We'll update the market when we have more preclinical data that we can show. But for now, due to IP reasons, we will just say that we performed interesting preclinical results. Very shortly about the Otsuka deal that we did last summer. As mentioned, total value of the deal 633, of which 33 was upfront.

That is excluding the royalty, which is in the low single digit up to double digit. This for us, is a validation of not only the company's deal-making capabilities, but that the target and also the interest that the big pharma has for inflammatory approaches with IL1RAP. It also will continue to be a non-diluted capital to fund our R&D in the future. As a conclusion, we have three pillars that we are working on, and our lead asset is nadunolimab, where we are targeting both high-risk MDS and pancreatic cancer. We are also, of course, tracking and following CAN10 closely, and for now, we're extremely excited about our bispecific that we will continue to update the market on the progress.

Next milestone coming up is the ASH presentation on December 13, on the MDS AML data, and we already reached our targets by announcing yesterday the second target for CAN14. We'll, in Q1, treat our first patient in the combination study, and by mid-2027, we'll have the top line data of the 2a part of the MDS AML study. With this initiative that we're running now, we have a cash runway with this current commitment into mid-2028. With that, I will open up for questions.

Operator

Sounds great. So maybe we can start. I guess, at a high level with IL1RAP. You mentioned hitting it too hard. It is just as bad as hitting it too narrowly. So what about the conformation of this accessory protein? I am trying to make the analogy to something like the PI3K pathway, which has seen some selective approaches. There are now some kind of broad pan-type approaches. So what about IL1RAP threads the needle here, specifically from the protein structure, and then what are some mechanisms of maybe potential escape or resistance that you have identified in some of the early work you have done?

Hilde Steineger
CEO, Cantargia

As you know, we have 500 clones targeting one target. That means that if you block it in one certain way, you can block IL-1 completely, like nadunolimab, so including IL-1 alpha and beta, while with CAN10, we can broaden it and hit broader. So we can also block IL-33 and 36 in combination with IL-1. So depending on how you block IL1RAP, you can then turn on or off different parts of the three receptor co-receptors.

That means we sort of can tweak it according to preclinical results, and we always start there. But also, we are, of course, scouting the market to see what other IL-33, 36, IL-1 has performed in clinical development. So by putting all the knowledge that is produced out there into thinking, "Oh well, if we block 1B, one alpha, and one beta, how would that turn out? Or if we block it broader, how would that turn out?" And then you just have to test it in a preclinical setting.

Operator

Mm-hmm. The upcoming disclosure at ASH, is there anything you can say about the duration of follow-up you will have for those patients? And then looking into that data, is there a certain data point beyond overall response rate maybe that you would want to emphasize for investors heading into ASH?

Hilde Steineger
CEO, Cantargia

Well, for now, the abstract is what we can disclose. We will update with more data for sure. It is not we as a company, Cantargia, that will present. It is MD Anderson that will present with the Department Head, Guillermo Garcia-Manero. There will be more data. What kind of data, I am not in the liberty to disclose right now.

Operator

Okay. I think the differential in outcomes from the PDAC data, with respect to IL1RAP expression was pretty interesting. I think it is also interesting too that even with the low expressors, you are still getting a very competitive, overall survival.

Hilde Steineger
CEO, Cantargia

Yep.

Operator

As PDAC becomes more competitive within the RAS space, both from a selective inhibitor, from pan-RAS approaches, there is an evolution of maybe taking more selective approaches to registrational development. I know this data is early, but when you see that kind of differential, does that change your philosophy about what a registrational effort maybe looks like down the line? Is that maybe a selective approach you would want to take versus an all-comer approach?

Hilde Steineger
CEO, Cantargia

Data only will tell us, but we will for sure measure retrospectively the IL1RAP levels in the tumor. We were planning before sort of this paradigm shift came in. We were planning a phase II-B, and proactively select high IL1RAP patients. If the same data holds true that there is a difference between high and low, we'll most probably have a biomarker approach into our phase II-B. It's too early to know. We don't know if that sort of difference holds up in combination with a RAS inhibitor.

Operator

Mm-hmm. Just appetite for BD or strategic optionality with the massive breadth of opportunity you have between autoimmune and immunology and oncology. As you're spinning out a lot of these development candidates, how do you prioritize maybe strategically partnering some of these assets emerging from your pipeline?

Hilde Steineger
CEO, Cantargia

Well, our plan A is always to go alone and fund our progress alone. However, if there is a good deal on the table, we'll certainly look at it, and we did take it as you saw with Otsuka.

But it is by definition, very hard to predict whether or not you can do a BD deal. We have to believe in our story that we can take all our products all the way to the market ourself. That is what we are planning for. Right now, the study is fully funded at MD Anderson with top-line data mid 2027, and we are embarking on phase I-B/II-A with PDAC. After that, the data will show whether or not we are a good partner candidate or if we can fund it on our own. Standard answer to a standard question, we will do both. Look at both.

Operator

Great. The Otsuka partnership, how much involvement or engagement will you have with Otsuka in terms of development or strategic decisions? Is it fully Otsuka's-

Hilde Steineger
CEO, Cantargia

Yes

Operator

exclusive rights to development there?

Hilde Steineger
CEO, Cantargia

Yes. They have acquired the product.

Operator

Okay.

Hilde Steineger
CEO, Cantargia

We are monitoring them and regularly updated, but it is totally in their hands.

Operator

Okay. You have nominated this next development candidate. Is there a certain cadence to which you would like to nominate candidates? Do you expect maybe an additional one next year or one to two every year? Or how do you think about that?

Hilde Steineger
CEO, Cantargia

Yeah. Good question. We have a lot of interesting candidates, but limited funding. Depending on our cash runway, how that looks in a year from now, we can run even faster. We have a handful of very interesting candidates, but taking them to IND readiness costs a lot of money. We will need to see how much of that we can fund ourself. We are also optimistic that some of these candidates we can do maybe in a partnership, in a co-development setting. There is no fixed number, but we have a lot of good options.

Operator

Awesome. Otto.

Speaker 3

Whenever I hear about this kind of big data set, I mean, you have 500 clones here.

You have candidates 200, you always think about the obvious thing today is how can you use AI to expedite the development?

Hilde Steineger
CEO, Cantargia

Yep.

Speaker 3

Is that something that you are doing?

Hilde Steineger
CEO, Cantargia

Yes. Of course, we use AI, and this as well. How and what the results are, I cannot disclose, but yes, we use AI. But we think that the target itself is so interesting, so that itself creates a lot of opportunities. And for now, preclinical results is what we are leaning or using as the determination for further development. But we can maybe increase our hit rate with AI.

Speaker 3

Just one other question. I was looking at the stock. The stock had a pretty big move back from like six to two. Was there anything in use or was it just from the market?

Hilde Steineger
CEO, Cantargia

It's a combination of several factors, I think. We had a shift in ownership structure where two pension funds merged into one, and in Sweden, this pension fund can only hold 10%. So, they had together more than 10%, so they had to reallocate some of their assets. Also, we did a rights issue before the summer, which was maybe not that highly appreciated. Also, the sentiment in general has gone against sort of-

Speaker 3

[Was this the AP1?]

Hilde Steineger
CEO, Cantargia

AP1, yeah. Yes. So, a shift in ownership, sentiment and sort of.

Speaker 3

They were sellers?

Hilde Steineger
CEO, Cantargia

Yes.

Operator

All right.

Hilde Steineger
CEO, Cantargia

All right.

Operator

Well, that is all we have for time.

Hilde Steineger
CEO, Cantargia

Yeah, exactly.

Operator

Thank you very much.

Hilde Steineger
CEO, Cantargia

Thank you.

Operator

Thanks for your attention, everyone.